Resumen del estudio
biotin-mediated targeting and produced ∼50-fold higher US signal than in DU145 tumors. In contrast, the clinical agent SonoVue showed no such tumor selectivity and ROS-responsive signal enhancement. MRI studies revealed a time-dependent signal drop only in A549 tumors treated with bt-PEG-BR@PFP, consistent with ROS-mediated nanobubble fusion. These results highlight bt-PEG-BR@PFP as a promising and clinically translatable platform for non-invasive, dual-modality imaging of tumor oxidative stress, with potential utility in various © 2026 The Author(s). Advanced Science published by Wiley‐VCH GmbH.
Detalles bibliográficos
- Autores: Jung W, Son Y, Lee DY, Jeon Y, Asaddudin M, Park SH
- Publicado en: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
- Fecha: 2026 May 13
- PMID: 42126812
- DOI: 10.1002/advs.202600071
📖 Leer el estudio completo en PubMed →
Esta evidencia se ha indexado automáticamente desde la base de datos PubMed (NCBI/NLM, US National Institutes of Health). El resumen mostrado es propiedad intelectual de sus autores y editorial.
